Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate.

Rajan R, Sabnani MK, Mavinkurve V, Shmeeda H, Mansouri H, Bonkoungou S, Le AD, Wood LM, Gabizon AA, La-Beck NM.

J Control Release. 2018 Feb 10;271:139-148. doi: 10.1016/j.jconrel.2017.12.023. Epub 2017 Dec 23.

2.

Nanoparticle Interactions with the Immune System: Clinical Implications for Liposome-Based Cancer Chemotherapy.

La-Beck NM, Gabizon AA.

Front Immunol. 2017 Apr 6;8:416. doi: 10.3389/fimmu.2017.00416. eCollection 2017.

3.

New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.

Gabizon AA, Patil Y, La-Beck NM.

Drug Resist Updat. 2016 Nov;29:90-106. doi: 10.1016/j.drup.2016.10.003. Epub 2016 Oct 29. Review.

PMID:
27912846
4.

Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.

Tian X, Warner SB, Wagner KT, Caster JM, Zhang T, Ohana P, Gabizon AA, Wang AZ.

Int J Radiat Oncol Biol Phys. 2016 Nov 1;96(3):547-55. doi: 10.1016/j.ijrobp.2016.06.2457. Epub 2016 Jul 1.

PMID:
27681751
5.

Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.

Golan T, Grenader T, Ohana P, Amitay Y, Shmeeda H, La-Beck NM, Tahover E, Berger R, Gabizon AA.

Cancer Med. 2015 Oct;4(10):1472-83. doi: 10.1002/cam4.491. Epub 2015 Jul 14.

6.

Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.

Tahover E, Patil YP, Gabizon AA.

Anticancer Drugs. 2015 Mar;26(3):241-58. doi: 10.1097/CAD.0000000000000182. Review.

PMID:
25415656
7.

Pharmacokinetics of low molecular weight heparin in patients with malignant tumors.

Nasser NJ, Na'amad M, Weinberg I, Gabizon AA.

Anticancer Drugs. 2015 Jan;26(1):106-11. doi: 10.1097/CAD.0000000000000176.

PMID:
25280062
8.

Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses.

Sabnani MK, Rajan R, Rowland B, Mavinkurve V, Wood LM, Gabizon AA, La-Beck NM.

Nanomedicine. 2015 Feb;11(2):259-62. doi: 10.1016/j.nano.2014.08.010. Epub 2014 Sep 6.

PMID:
25200609
9.

Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal Doxorubicin.

Soloman R, Gabizon AA.

Clin Lymphoma Myeloma. 2008 Feb;8(1):21-32. Review.

PMID:
18501085
10.

Pros and cons of the liposome platform in cancer drug targeting.

Gabizon AA, Shmeeda H, Zalipsky S.

J Liposome Res. 2006;16(3):175-83. Review.

PMID:
16952872
11.

Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.

Gabizon AA, Tzemach D, Horowitz AT, Shmeeda H, Yeh J, Zalipsky S.

Clin Cancer Res. 2006 Mar 15;12(6):1913-20.

12.

Cardiac safety of liposomal anthracyclines.

Ewer MS, Martin FJ, Henderson C, Shapiro CL, Benjamin RS, Gabizon AA.

Semin Oncol. 2004 Dec;31(6 Suppl 13):161-81. Review.

PMID:
15717742
13.

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.

Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA.

Semin Oncol. 2004 Dec;31(6 Suppl 13):106-46. Review.

PMID:
15717740
14.

Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.

Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA.

Semin Oncol. 2004 Dec;31(6 Suppl 13):53-90. Review.

PMID:
15717738
15.
16.

Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects.

Gabizon AA.

J Drug Target. 2002 Nov;10(7):535-8. Review. No abstract available.

PMID:
12683720
17.

Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.

Lyass O, Hubert A, Gabizon AA.

Clin Cancer Res. 2001 Oct;7(10):3040-6.

18.
19.

Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet.

Gabizon AA.

Clin Cancer Res. 2001 Feb;7(2):223-5. No abstract available.

20.

Reduction of the systemic toxicity of cisplatin by intra-arterial hepatic route administration for liver malignancies.

Vexler AM, Mou X, Gabizon AA, Gorodetsky R.

Int J Cancer. 1995 Mar 3;60(5):611-5.

PMID:
7532157
21.

Liposomal anthracyclines.

Gabizon AA.

Hematol Oncol Clin North Am. 1994 Apr;8(2):431-50. Review.

PMID:
8040147
23.

In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release.

Horowitz AT, Barenholz Y, Gabizon AA.

Biochim Biophys Acta. 1992 Aug 24;1109(2):203-9.

PMID:
1520697

Supplemental Content

Loading ...
Support Center